Bacteriocin-like substance from Bacillus amyloliquefaciens shows remarkable inhibition of Acanthamoeba polyphaga

Parasitology Research

Volumn 108, Issue 3, 2011, Pages 687-691

  Benitez, Lisianne Brittes ^a   Caumo, Karin ^a   Brandelli, Adriano ^a   Rott, Marilise Brittes ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; BACTERIOCIN LBM 5006; UNCLASSIFIED DRUG;

ACANTHAMOEBA; ACANTHAMOEBA POLYPHAGA; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; BACILLUS AMYLOLIQUEFACIENS; BIOASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; HAPLORHINI; IC 50; MICROBIAL MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; TROPHOZOITE; VERO CELL;

ACANTHAMOEBA; AMEBICIDES; ANIMALS; BACILLUS; BACTERIAL PROTEINS; BACTERIOCINS; CELL LINE; CERCOPITHECUS AETHIOPS; VERO CELLS;

ACANTHAMOEBA POLYPHAGA; BACILLUS AMYLOLIQUEFACIENS;

EID: 79955931900     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-010-2114-5     Document Type: Article

References (26)

1. Arrighi RB, Nakamura C, Miyake J, Hurd H, Burgess JG (2002) Design and activity of antimicrobial peptides against sporogonic-stage parasites causing murine malarias. Antimicrob Agents Chemother 46(7):2104-2110 (Pubitemid 34665903)
2. Awwad ST, Petroll WM, McCulley JP, Cavanagh HD (2007) Updates in Acanthamoeba keratitis. Eye Contact Lens 33:1-8 (Pubitemid 46114822)
3. Carvalho FR, Foronda AS, Mannis MJ, Höfling-Lima AL, Belfort R Jr, de Freitas D (2009) Twenty years of Acanthamoeba Keratitis. Cornea 28:516-519
4. Clarke DW, Niederkorn JY (2006) The pathophysiology of Acanthamoeba keratitis. Trends Parasitol 22:175-180
5. De Jonckheere JF (1980) Growth characteristics, cytopathic effect in cell culture, and virulence in mice of 36 type strains belonging to 19 different Acanthamoeba spp. Appl Environ Microbiol 39:681-685
6. Fiori PL, Mattana A, Dessi D, Conti S, Magliani W, Polonelli L (2006) In vitro acanthamoebicidal activity of a killermonoclonal antibody and a synthetic peptide. J Antimicrob Chemother 57:891-898
7. Gopinathan U, Sharma S, Garg P, Rao GN (2009) Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Indian J Ophthalmol 57:273-279
8. Goze I, Alim A, Dag S, Tepe B, Polat ZA (2009) In vitro amoebicidal activity of Salvia staminea and Salvia caespitosa on Acanthamoeba castellanii and their cytotoxic potentials on corneal cells. J Ocul Pharmacol Ther 25:293-298
9. Illingworth CD, Cook SD (1998) Acanthamoeba keratitis. Surv Ophthalmol 42:493-508 (Pubitemid 28272739)
10. Kumar R, Lloyd D (2002) Recent advances in the treatment of Acanthamoeba keratitis. Clin Infect Dis 35:434-441 (Pubitemid 34852574)
11. Lisboa MP, Bonatto D, Bizani D, Henriques JAP, Brandelli A (2006) Characterization of a bacteriocin-like substance produced by Bacillus amyloliquefaciens isolated from the Brazilian Atlantic Forest. Int Microbiol 9:111-118 (Pubitemid 44047823)
12. Lloyd D, Turner NA, Khunkitti W (2001) Encystation in Acanthamoeba castellanii: development of biocide resistance. J Eukaryot Microbiol 48:11-16 (Pubitemid 32180364)
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:267-275
14. Ma P, Visvesvara GS, Martinez AJ, Theodore FH, Daggett PM, Sawyer TK (1990) Naegleria and Acanthamoeba infections: review. Rev Infect Dis 12:490-513 (Pubitemid 20174604)
15. Marciano-Cabral F, Cabral GA (2003) Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 16:273-307 (Pubitemid 36519813)
16. Martinez MS, Gonzalez-Mediero G, Santiago P, Rodriguez de Lope A, Diz D, Visvesvara GS (2000) Granulomatous amebic encephalitis in a patient with AIDS: isolation of Acanthamoeba sp. group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J Clin Microbiol 38:3892-3895
17. Mills R (2003) Microbial keratitis, what's the preferred initial therapy? View 1: corneal scraping and combination antibiotic therapy is indicated. Br J Ophthalmol 87:1167-1169
18. Motta AS, Brandelli A (2002) Characterization of an antibacterial peptide produced by Brevibacterium linens. J Appl Microbiol 92:63-71
19. Papagianni M (2003) Ribosomally synthesized peptides whit antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 21:465-499
20. Polat ZA, Vural A, Tepe B, Cetin A (2007) In vitro amoebicidal activity of four Allium species on Acanthamoeba castellanii and their cytotoxic potentials on corneal cells. Parasitol Res 101:397-402
21. Reddy KVR, Yedery RD, Aranha C (2004) Review: antimicrobial peptides: premises and promises. Int J Antimicrob Agents 24:536-547 (Pubitemid 39536106)
22. Ródio C, Vianna DR, Kowalski KP, Panatieri LF, von Poser G, Rott MB (2008) In vitro evaluation of the amebicidal activity of Pterocaulon polystachyum (Asteraceae) against trophozoites of Acanthamoeba castellanii. Parasitol Res 104:191-194
23. Sacramento RS, Martins RM, Miranda A, Dobroff ASS, Daffre S, Foronda AS, De Freitas D, Schenkman S (2009) Differential effects of α-helical and β-hairpin antimicrobial peptides against Acanthamoeba castellanii. Parasitology 136:813-821
24. Saragoza R (1994) Ecology of free-living amoebae. Crit Rev Microbiol 20:225-241
25. Schuster FL, Visvesvara GS (1998) Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas. J Eukaryot Microbiol 45:612-618 (Pubitemid 29009976)
26. Schuster FL, Visvesvara GS (2004) Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 34:1001-1027 (Pubitemid 39106843)